51
|
Lu J, Chen X, Zhang X, Wang M, Wu M, Yu J, Chen D. IKBKE Promotes Radioresistance of Glioblastoma through AKT/FOXO3a Pathway. Int J Radiat Oncol Biol Phys 2023; 117:S139. [PMID: 37784354 DOI: 10.1016/j.ijrobp.2023.06.547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Glioblastoma is an intracranial highly malignant primary tumor, and postoperative radiotherapy is a common treatment of glioblastoma. While radiotherapy resistance of glioblastoma is an important reason for treatment failure. IKBKE is overexpressed in gliomas, but its role in radiotherapy is unknown. This study confirmed that IKBKE can directly phosphorylate AKT protein to regulate FOXO3a, thus promoting the radioresistance of glioblastoma, and proposed a new therapeutic strategy to enhance the efficacy of radiotherapy. MATERIALS/METHODS We used flow cytometry, tunel staining, plate cloning, a cell counting kit and WB to confirm the effects of IKBKE and FOXO3a on radioresistance of glioblastoma, and immunofluorescence and WB were used to detect the expression of γ-H2AX. Subcutaneous tumor formation in mice and immunohistochemical staining was performed. IP combined with mass spectrometry, immunofluorescence, endogenous and exogenous IP were used to confirm the interaction between IKBKE and AKT. Point mutation, IP and WB were used to confirm the phosphorylation site of AKT. IP and some small molecule inhibitors were used to confirm the relationship between IKBKE, AKT and PI3K. The effect of IKBKE on FOXO3a was confirmed by WB and qPCR. The protein relationship among IKBKE, FOXO3a and 14-3-3 was confirmed by CHX, MG132, ubiquitin test, immunofluorescence and IP. The above experiments were carried out to verify the effect of Amlexanox, an IKBKE inhibitor, on glioblastoma. And its pharmacokinetics in the brain was determined by LC-MS to provide a theoretical basis for further clinical use. RESULTS It was found that IKBKE could increase the radioresistance of glioblastoma in vitro and in vivo. IKBKE could directly phosphorylate AKT, and its phosphorylation sites were Ser473 and Thr308. We also certified that IKBKE activated AKT independent of PI3K. IKBKE inhibited the expression of FOXO3a on protein level, promoted its ubiquitin degradation, enhanced its interaction with 14-3-3, and inhibited its transportation into the nucleus. FOXO3a can increase the radiosensitivity of glioblastoma. Amlexanox, an IKBKE inhibitor, can inhibit the radiosensitivity of glioblastoma and partially pass through the blood-brain barrier to enhance the radiosensitivity of intracranial tumors. CONCLUSION IKBKE can activate AKT independent of PI3K by directly phosphorylating AKT Ser473 and Thr308, thus increasing the phosphorylation of FOXO3a. Phosphorylated FOXO3a promoted its ubiquitin degradation, and inhibited its transportation into the nucleus, causing radioresistance in glioblastoma. IKBKE inhibitor Amlexanox can pass through the blood-brain barrier and increase the radiosensitivity of intracranial tumor cells.
Collapse
|
52
|
Yu J, Feng Y, Pi S, Li Y. Effects of the PARP Inhibitor Niraparib on the Radiosensitivity of Human Lung and Cervical Cancer Cells. Int J Radiat Oncol Biol Phys 2023; 117:e274. [PMID: 37785032 DOI: 10.1016/j.ijrobp.2023.06.1246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) DNA damage repair (DDR) initiated after DNA damage may lead to a decreased radiosensitivity of tumor cells or even radiation resistance. Previous studies indicate that PARP inhibitors block the repair of DNA single-strand breaks (SSBs), and unrepaired SSBs may continuously accumulate and form double-strand breaks (DSBs) that promotes tumor cell death. Studies have also shown that PARP inhibitors act synergistically with RT to inhibit DDR. In this study, we aim to investigate the effect of Niraparib, a clinically approved PARP inhibitor on the radiosensitivity of human lung and cervical cancer cells, and preliminarily explore the underlying mechanism. MATERIALS/METHODS The human lung cancer cell line A549 and human cervical cancer cell line Siha were both treated with niraparib (for 1h), or X-ray (4Gy), or Niraparib (for 1h) combined with X-ray (4Gy). The effect was examined via measurements of cell proliferation by the cell counting kit-8 assay, and cell viability was detected by clone formation assays. Cell apoptosis and cell cycle distribution were investigated by flow cytometry. RESULTS In human lung and cervical cancer cell lines, Niraparib combined with radiation therapy significantly inhibited cell proliferation. The proportion of apoptotic cells in cell lines treated with Niraparib plus radiation (the combination group) was significantly higher compared with control, radiation-only, and Niraparib-only groups. Additionally, the proportion of A549 cells in the G2/M phase was significantly increased in the combination group compared with the radiation-only group. CONCLUSION The results support that PARP inhibitor Niraparib increases the radiosensitivity of tumor cells, promotes their apoptosis, and induces cell cycle redistribution. The possible mechanism is associated with the inhibition of radiation-induced DNA damage repair.
Collapse
|
53
|
Smith J, Yu J, Gordon L, Chilkuri M. Financial Toxicity and Out-of-Pocket Costs for Patients with Head and Neck Cancer: An Australian Perspective. Int J Radiat Oncol Biol Phys 2023; 117:e260. [PMID: 37784999 DOI: 10.1016/j.ijrobp.2023.06.1213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Financial toxicity is under-investigated for patients with head and neck cancer (HNC). The aim of this study was to quantify and describe the financial toxicity and out-of-pocket costs for patients with HNC in regional Australia and to consider its relationship with quality of life. MATERIALS/METHODS A cross-sectional survey was administered to patients with mucosal HNC who were disease free and 1-3 years after completion of radiotherapy at a regional tertiary hospital in Australia. The survey included questions on socio-demographics, out-of-pocket expenses, and health-related quality of life (HRQoL) measured with the FACT-H&N. Financial toxicity was evaluated using the Financial Index of Toxicity (FIT) survey, which scores financial toxicity on a scale of 0-100 (higher score indicating higher financial toxicity). The relationship between high financial toxicity scores (top quartile) and HRQoL was explored. RESULTS Of 57 total patients, 41 (72%) reported out-of-pocket expenses at a median of AU$1,796 (interquartile range AU$2,700) and a maximum of AU$25,050. The overall median FIT score was 13.9 (interquartile range 19.5) and patients with high financial toxicity (n = 14) reported poorer HRQoL (76.5 vs 114.5, p < 0.001). Patients who were not married had a higher financial toxicity score (23.1 vs 11.1, p = 0.01). Similarly, those participants with lower levels of education had higher financial toxicity (19.3 vs 11.1, p = 0.06). Participants with private health insurance were found to have lower rates of financial toxicity (8.3 vs 17.6, p = 0.01). Medications (41%, median AU$400), dietary supplements (41%, median AU$600), travel (36%, median AU$525) and dental (29%, AU$388) were the most common out-of-pocket expenses. Only nineteen patients (33%) reported that a member of their treating team had asked if they have any financial concerns. Participants living in rural locations (> 100km from the hospital) had higher out-of-pocket expenses (AU$2655 vs AU$730, p = 0.01). CONCLUSION Financial toxicity is a significant issue for a significant proportion of patients with head and neck cancer which was associated with a reduced HRQoL. All clinicians should consider asking patients with HNC about financial concerns and be aware of what financial support is available in their region. Interventions are required to reduce the burden of financial toxicity for patients with HNC.
Collapse
|
54
|
Shi X, Wang P, Li Y, Xu J, Yu J, Teng F. Using MRI Radiomics to Predict the Efficacy of Immunotherapy for Brain Metastasis in Patients with Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e65-e66. [PMID: 37785933 DOI: 10.1016/j.ijrobp.2023.06.791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Immune-checkpoint inhibitors (ICIs) combined with chemotherapy has been widely used in the first-line treatment of small cell lung cancer (SCLC) patients. However, the efficacy of ICIs for patients with brain metastases (BMs) of SCLC is limited. There are no effective factors to predict the efficacy. We developed and validate a model to predict intracranial efficacy for ICIs in patients with BMs from SCLC by using MRI radiomics. MATERIALS/METHODS In this study, we collected 101 SCLC patients with BMs treated with ICIs. They clinical characteristics and pre-treatment Magnetic Resonance Imaging (MRI) were collected. Seventy cases collected from our hospital as training cohort and 31 cases collected from another hospital as an independent validation cohort. Brain metastatic lesions were contoured on ITK-SNAP software and 3748 radiomic features capturing both intra- and peritumoral texture patterns were extracted. The primary endpoint of this study was intracranial overall response rate (ORR). Intraclass correlation coefficient (ICC) and random forest (RF) model were used to select radiomic features. The top 10 selected radiomic features were adopted to build prognostic models by using logistic regression. Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) was chosen as the metric to assess model performances. We also performed a nomogram based on a multivariate logistic regression model includes radiomic and clinical features to predict ICIs intracranial efficacy. RESULTS The clinical characteristics including number of treatment lines and concurrent brain radiotherapy, ten intratumoral signatures and one peritumoral signatures were found significantly associated with ICIs intracranial efficacy. Predictors contained in the individualized prediction nomogram included the radiomics signature, and clinical features. The model showed favorable discrimination with a C-index of 0.861[95% CI: 0.779-0.943] and AUC of 0.861[95% CI: 0.778- 0.944] in training cohort and with a C-index of 0.812[95% CI: 0.647-0.978] and AUC of 0.812[95% CI:0.646-0.979] in the test cohort. CONCLUSION Radiomic features from pre-treatment MRI images were predictive for intracranial efficacy in SCLC patients with BMs. Pre-treatment radiomics may allow early prediction of benefit and expedite more aggressive treatment for high-risk patients and it has to be further explored as predictor of outcome in a larger series of patients.
Collapse
|
55
|
Zhang J, Shang S, Wang F, Wang R, Shangguan J, Zhang Y, Wu M, Ma J, Yu J, Chen D. The Baseline Serum Lipid Levels and Outcomes of NSCLC Patients Receiving Immunotherapy Combined or Non-Combined with Radiotherapy: A Single Center Retrospective Study. Int J Radiat Oncol Biol Phys 2023; 117:e11. [PMID: 37784645 DOI: 10.1016/j.ijrobp.2023.06.670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) In recent years, many studies have shown that lipids and lipid-like substances are key regulatory factors in tumor development and play an important role in immune regulation. However, it remains unclear whether serum lipids influence the outcome of immunotherapy. Therefore, determining the serum lipid levels of the immune treatment-beneficiary population may be valuable. The aim of this study is to evaluate the prognostic value of baseline serum lipid levels in non-small cell lung cancer (NSCLC) patients receiving immunotherapy. MATERIALS/METHODS We retrospectively included 294 patients with stage III-IV NSCLC who received immunotherapy continuously from December 2018 to November 2021 at our hospital, collecting their pre-treatment lipid levels, such as total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Of these, 160 receiving immunotherapy without combined radiotherapy (ICIs-nRT) and 134 combined with radiotherapy (iRT). The endpoint was the correlation between pre-treatment serum lipid levels and overall survival (OS), as well as progression-free survival (PFS). The X-tile tool was used to determine the optimal cut-off value of the indicators. The Kaplan-Meier survival curves were used to calculate OS and PFS and log rank tests were used for comparison. And the Cox proportional hazard model were used for univariate and multivariate analysis. RESULTS In all 294 patients, low TG, low TC, and low HDL-C predicted poor OS (P<0.001) and poor PFS (P<0.05). Low LDL-C was associated with poor OS (P = 0.0001). Among 160 patients receiving ICIs-nRT and 134 iRT patients, low levels of TG (P = 0.0134, 0.0024), TC (P = 0.0003, 0.0023), HDL-C (P = 0.0004, 0.0043), and LDL-C (P = 0.0003, 0.0419) were associated with worse OS compared to high levels of them. In the ICIs-nRT patients, low HDL-C predicted poor PFS (P = 0.0011). In 134 iRT patients, low levels of TG (P = 0.0017), TC (P = 0.0028), and LDL-C (P = 0.0330) were poor prognostic factors for PFS. In the univariate and multivariate analysis with OS in all patients, TG and HDL-C were independent risk factors, while TG was an independent risk factor in the analysis with PFS. In ICIs-nRT patients, HDL-C was an independent prognostic factor for patients' OS and PFS. In iRT patients, both TG and HDL-C were prognostic risk factors for OS. CONCLUSION These data confirm that higher serum lipid levels are associated with better outcomes in patients with NSCLC undergoing immunotherapy. Serum lipids may identify tumors that are more likely to respond to immunotherapy. Radiation therapy may affect lipid metabolism within the body to enhance the efficacy of immunotherapy.
Collapse
|
56
|
Liu C, Li X, Lei T, Yue J, Yu J. Single-Cell Dissection of Concurrent Chemoradiotherapy-Induced Immunosenescence in Cervical Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e246. [PMID: 37784963 DOI: 10.1016/j.ijrobp.2023.06.1181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Immunosenescence could attenuate effective anti-tumor immune response, but it's role in the tumor microenvironment following concurrent chemoradiotherapy (CCRT) in cervical cancer (CC) remains largely unknown. We aimed to investigate CCRT induced immunosenescence and its clinical implications in CC at single-cell resolution. MATERIALS/METHODS A total of 11326 cells from single-cell RNA sequencing data derived from five post-CCRT CC tumor samples were analyzed by bioinformatics for immunosenescence. Functional enrichment analysis including Gene Ontology (GO) and Gene Set Variation analysis was performed to identify and assess the molecular heterogeneity of cell subclusters. Kaplan-Meier survival analysis was performed in the bulk RNA-sequencing data included 253 patients with CC obtained from the The Cancer Genome Atlas. RESULTS We identified senescent and non-senescent cell clusters in tumor-associated macrophages (TAMs), CD8+ T cells and NK cells after CCRT based on the senescence-related genes expression. GO analysis showed that antigen processing and presentation pathways were enriched in the non-senescent TAMs, while the response to hypoxia and oxidative stress were enriched in the senescent TAMs, which repressed the anti-tumor immunity. We further found that the abundance of senescent TAMs was associated with shorter overall survival (OS) of patients with CC (P<0.001). Moreover, compared to senescent CD8+ T, non-senescent CD8+ T exhibited higher cytotoxicity and exhausted signature scores, and increased enrichment of T cell proliferation, differentiation and activation pathways. In addition, the high proportion of non-senescent NK cell was also associated with better OS of CC patients (P = 0.008). CONCLUSION We revealed the potential immune suppressive characteristics of CCRT induced senescent immune cells at single-cell resolution, which provides promising therapeutic targets for CC patients.
Collapse
|
57
|
Ross RB, Yu J, Gadwa J, Darragh LB, Knitz M, Nguyen D, Hoen M, Olimpo N, Corbo S, D'Alessandro A, Karam SD. Enhancing Immune-Mediated Radiotherapy Efficacy in Murine Models of Head and Neck Cancer through Peroxisome Proliferator-Activated Receptor Modulation. Int J Radiat Oncol Biol Phys 2023; 117:S103. [PMID: 37784273 DOI: 10.1016/j.ijrobp.2023.06.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The tumor microenvironment (TME) in HPV-unrelated head and neck cancer (HNC) is considered to be immunologically "cold," and immunometabolic adaptations to radiotherapy (RT) can exacerbate these conditions and lead to radioresistance. Peroxisome proliferator-activated receptor-α (PPARα) agonism may improve the immune response to RT by reducing glucose scarcity through upregulation of fatty acid utilization in cancer cells. Our clinical trial data shows that high serum oleic acid (OA), a PPAR ligand, correlates with response to radioimmunotherapy. MATERIALS/METHODS Orthotopic buccal tumor implantations of MOC2 and LY2 HNC cell lines were performed in C57BL/6 and BALB/c mice, respectively. Mice were placed on a high OA diet (38% kcal from OA) 3 weeks prior to tumor implantation. Control diet consisted of 1% kcal from OA. In vitro RT was performed to characterize the metabolic effects on the cancer cell lines. For in vivo studies, tumors were irradiated upon reaching 100 mm^3 with three 8 Gy fractions, given every 4-5 days. The PPARα agonist fenofibrate (FF, 100mg/kg/day) was given via oral gavage or intraperitoneal injection starting 5 days after RT. Tumor volume and overall survival were measured as objective outcomes, and flow cytometry was used to characterize the immune landscape of the tumor, blood, and lymph nodes. Mass spectrometry was employed for bulk proteomics and metabolomics on serum samples, and stable isotope labeling was performed on CD8 T cells from treated mice ex vivo. Extracellular flux analyses were performed on tumor cells and CD8 T cells to determine metabolic phenotypic changes. RESULTS In vitro cytotoxicity was met for MOC2 and LY2 cancer cells in 100 uM FF and OA in comparison to solvent (p<0.01). Extracellular flux analyses show that RT upregulates the glycolytic phenotype of MOC2 and LY2 cancer cells; and that FF and/or OA decrease the glycolytic capacity of the cancer cells. Ex vivo extracellular flux analyses showed increased glycolytic capacity of CD8 T cells in mice treated with FF in comparison to RT alone. RT in combination with FF significantly improved tumor volume response in comparison to RT alone (mean 99.4 vs 182.7 mm^3, p = 0.001) and was comparable to combination radioimmunotherapy (with anti-PDL1 therapy; mean 99.4 vs. 132.3 mm^3). Unexpectedly, OA negated this improvement in efficacy in both MOC2 and LY2 tumor models; mice on the high OA diet had significantly higher average body weight (p<0.01). Significant changes in adaptive immune response were observed within the TME with the addition of FF. This was mirrored by changes in serum metabolomics. CONCLUSION PPARα agonism improved the efficacy of RT in murine HNC models and could be considered in future translational clinical trial design.
Collapse
|
58
|
Teng F, Wang P, Yin T, Xing L, Yu J. Analyzing the Predictive Effects of PD-L1 Expression, Early Changes of bTMB and Circulated CD8+T Cells during Treatment for Responses of RT Combined with ICI in NSCLC. Int J Radiat Oncol Biol Phys 2023; 117:e262-e263. [PMID: 37785003 DOI: 10.1016/j.ijrobp.2023.06.1218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The beneficial role of immunotherapy and the clinical relevance of current biomarkers remain inconclusive; thus, appropriate strategies and reliable predictors need further definition. A rational combination of biomarkers is needed. Here, we estimated potential predictive factors for responses of radiotherapy (RT) combined with immune checkpoint inhibitor (ICI) in a phase II trial to determine the efficacy and safety of combination of moderate hypofractionated RT with ICI in patients with oligometastatic NSCLC (NCT03557411). MATERIALS/METHODS Pretreatment tumor tissue samples and longitudinal blood were collected for immune and tumor biomarker analysis. We examined pre-treatment (pre-ICI) PD-L1 expression in tumor cells. Circulating tumor cell (CTC), PD-L1+CTC, blood tumor mutation burden (bTMB), CD8+T cells, CD4+T cells, NK cells, B cells in circulation were acquired pre-ICI and 1 month after ICI starting (1-mth). In addition, early changes of CTC (CTC), PD-L1+CTC (PD-L1+CTC), bTMB (bTMB), CD8+T cells (CD8+T cells), CD4+T cells (CD4+T cells), NK cells (NK cells), B cells (B cells) were also analyzed to estimate the predictive effects for treatment. RESULTS High pre-ICI bTMB and increased CD8+T cells at 1 month was associated with better PFS (p = 0.016; p = 0.006). Interaction analyses revealed that each combination of two markers in the 5 markers including PD-L1, pre-ICI bTMB, 1-mth bTMB, 1-mth CD8+T cells and CD8+T cells was significantly associated with PFS, except for CTC, PD-L1+CTC, CD4+T cells, NK cells and B cells in circulation due to low power. Unsupervised cluster analysis based on these markers revealed three sub-cohorts. Cohort-1 was overrepresented by patients with progressive disease (81%) of whom were negative for 3-4 of the 5 biomarkers. Cohort-3 was overrepresented by patients with partial response (70%) of whom were positive for 3-4 of the 5 biomarkers. Survival analyses of the 3 cohorts indicated a significant association with PFS (p = 0.017). CONCLUSION This study suggests that a combination of PD-L1 expression, early changes of bTMB and circulated CD8+T cells as a better predictive biomarker for response to RT combined with ICI. Consequently, refinement of this set of biomarkers and validation in a larger set of patients is warranted.
Collapse
|
59
|
Cai G, Meng X, Yu J. The Predictive Value of Changes in Basal Myocardial F-18 Fluorodeoxyglucose Uptake for Cardiotoxicity in Locally Advanced Esophageal Cancer Patients Receiving Definitive Radiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e285. [PMID: 37785059 DOI: 10.1016/j.ijrobp.2023.06.1272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To investigate the predictive value of changes in myocardial 18F-FDG uptake for major adverse cardiac events (MACEs) in locally advanced esophageal cancer patients receiving definitive radiotherapy. MATERIALS/METHODS Between August 2012 and January 2018, 400 patients with stage II-III esophageal cancer receiving definitive radiotherapy at two institutions were divided into the training (n = 240) and external validation cohorts (n = 160). All patients underwent FDG-PET imaging within 1 week before treatment and 3 months after treatment. Myocardium delineation was performed by Carimas software (version 2.10) based on the AHA 17-segment model. When contouring the left ventricle, the myocardium was automatically divided into basal (segments 1-6), middle (segments 7-12), and apical (segments 13-16) regions, and the mean dose and FDG uptake parameters of each region were obtained by Carimas. Our primary endpoint was MACEs. Patient clinicopathologic factors, dosimetric parameters for the whole heart and cardiac substructures, and myocardial changes within the three regions on 18F-FDG PET were utilized to seek the best predictive models for cardiotoxicity. To avoid multicollinearity between dose-volume histogram (DVH) parameters, we selected the variables with the lowest Akaike Information Criterion (AIC) value from the DVH parameters of the same cardiac structure for the actual modeling procedure. Competing risk analysis and Cox regressions analysis were performed. The predictive performance of the models was evaluated using the area under the receiver operating characteristic curve (AUC) and Brier score. RESULTS At a median follow-up interval of 78 months, 28 patients (11.7%) developed MACEs. The basal region of the myocardium received the highest radiation dose, followed by the middle and the apex region. The basal myocardial SUVmax and SUVmean significantly increased after radiotherapy while the apical and middle myocardial SUVmax and SUVmean not significantly increased. In univariate analysis, age, pre-existing cardiac disease, changes in pre- and post-treatment basal myocardial SUVmax and SUVmean (∆SUVmax and ∆SUVmean), and dosimetric parameters for MHD, mean LCX, mean LAD, and mean LV dose were associated with an increased hazard of MACEs. Multivariate analysis showed that basal ∆SUVmean retained significance after adjusting for age, pre-existing cardiac disease, and dosimetric parameters for whole heart and cardiac substructures. The AUCs and Brier scores demonstrated favorable predictive accuracies of the model's integrating variables with significant difference in multivariate analysis when predicting MACEs in the training and validation cohorts. CONCLUSION ∆SUVmean was an independent indicator of MACE in locally advanced esophageal cancer patients receiving definitive radiotherapy. Changes in basal myocardial FDG uptake is a promising biomaker for predicting radiation-induced cardiotoxicity.
Collapse
|
60
|
Teng F, Wang P, Yu J. Using CT Radiomics and Machine Learning to Distinguish Radiotherapy vs. Immune Checkpoint Inhibitor-Induced Pneumonitis in Non-Small Cell Lung Cancer Patients. Int J Radiat Oncol Biol Phys 2023; 117:e65. [PMID: 37785931 DOI: 10.1016/j.ijrobp.2023.06.789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Both radiotherapy (RT) and immune checkpoint inhibitors (ICIs) may induce pneumonitis which is difficult to distinguish clinically. We tested the utility of computed tomography (CT) in identifying the cause of pneumonitis in patients with non-small cell lung cancer (NSCLC) who received RT, ICIs and RT combined with ICIs (RT+ICIs). MATERIALS/METHODS In this study, we analyzed the clinical characteristics and CT morphology of 130 NSCLC patients who developed pneumonitis after receipt of ICIs only (n = 50), thoracic RT only (n = 50) (ICIs only + RT only, the training cohort, n = 100), and RT+ICIs (the test cohort, n = 30). CT radiomics features were extracted using 3D-Slicer software and selected using LASSO regression for training a random forest (RF) classifier and a linear discriminant analysis (LDA) classifier to discern pneumonitis etiology. Patients who received RT or ICIs only were defined as the training cohort since the cause of their pneumonitis was readily identifiable. Patients who received RT+ICIs were defined as the test cohort and the cause of their pneumonitis were determined by clinicians as the ground truth. RESULTS In the study, the median time from the initiation of treatment to pneumonitis was 1.9 months in RT+ICIs patients, which was shorter than 2.5 months in RT only and 2.7 months in ICIs only patients. In addition, the patients in RT+ICIs group have more high grade (grade 3-4) pneumonitis compared to patients in ICIs only or RT only group (p<0.05). Pneumonitis after the combined therapy was not a simple superposition mode of RP and CIP, resulting in the distinct characteristics of both RT and ICIs-related pneumonitis. (1) Some cases resembled RP with sharp borders in the ipsilateral lung and others resembled the bilateral distribution of typical CIP, while some patients exhibit an intermediate morphology; (2) Some pneumonitis occurred in the areas of low and medium doses of radiation rather than the high-dose radiation areas similar to RP; (3) Some pneumonitis was initially limited to the ipsilateral lung that had received radiation and then developed in bilateral lungs. The RF classifier showed favorable discrimination between CIP and RP with an area under the receiver operating curve (AUC) of 0.859 (95% CI: 0.7884-0.9292) in the training cohort and 0.851 (95% CI: 0.6998-1) in the test cohort. The simplified LDA classifier consisting of 7 LASSO-selected features achieved an AUC of 0.881 (95% CI: 0.815-0.947) in the training cohort and 0.842 (95% CI: 0.686-0.997) in the test cohort. CONCLUSION RT and ICIs-related pneumonitis exhibit distinct clinical characteristics and morphologic features on CT. CT radiomics-based classifiers could provide a noninvasive method to identify the predominant etiology in NSCLC patients who developed pneumonitis after thoracic RT and ICIs.
Collapse
|
61
|
Dai L, Huang J, Hu L, Wu J, Wang J, Meng Q, Sun F, Duan Q, Yu J. Efficacy of Nimotuzumab plus Concurrent Chemo-Radiotherapy for Unresectable Esophageal Cancer: A Real-World Study. Int J Radiat Oncol Biol Phys 2023; 117:e354. [PMID: 37785223 DOI: 10.1016/j.ijrobp.2023.06.2432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The esophageal cancer ranked 7th in the morbidity of malignant cancer and the 6th contributed to carcinoma deaths. Most patients are diagnosed of advanced stage at first visiting. The 5-year survival rate of unresectable esophageal cancer is about 20% after the standard treatment of concurrent chemo-radiotherapy. Nimotuzumab, a humanized anti-EGFR antibody, has shown good efficacy and low toxicity in epithelial tumors. This two-center, real-world study evaluated the efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in unresectable esophageal squamous cell carcinoma (ESCC). MATERIALS/METHODS Totally 503 eligible unresectable ESCC patients from Jan 2014 to Dec 2020 were included. 1:2 nearest neighbor propensity score matching (PSM) was performed to match the Nimo group (nimotuzumab plus concurrent chemo-radiotherapy) and CRT group (concurrent chemo-radiotherapy), and the covariates included age, gender, tumor location, lesion length, TNM stage, clinical stage, and radiotherapy dose. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). RESULTS A total of 61 patients were in Nimo group which received nimotuzumab (200 mg/w, 4-6 weeks) combined with concurrent chemo-radiotherapy (chemotherapy: S-1/FP/TP/DP for 2-4 cycles; radiotherapy: 2DRT,3D-CRT or IMRT, 50-70 Gy in 25-35 fractions) and 107 patients in CRT group only received concurrent chemo-radiotherapy. The baseline characteristics were well balanced between the two groups. The efficacy of Nimo group was better than that of CRT group. The ORR was 85.2% vs. 71.0%, (P=0.037), the DCR was 98.4% vs. 91.6%, (P>0.05). The median PFS was 28.07 months vs. 19.54 months, and the 1-, 3- and 5-year PFS rates were 78.2% vs. 72.9%, 37.5% vs. 28.3%, and 29.1% vs. 21.3%, respectively (HR: 0.6860, 95% CI: 0.4902-0.9600, P=0.034). The median OS was 34.93 months vs. 24.30 months and the 1-, 3- and 5-year OS rates were 88.5% vs. 81.3%, 46.8% vs. 35.2% and 37.4% vs. 28.0%, respectively (HR: 0.6701, 95% CI: 0.4792-0.9372, P=0.024). The adverse events including radiation esophagitis, radiation pneumonitis, bone marrow suppression, nausea, vomiting, and rash were no significantly different between the two groups (P>0.05). CONCLUSION Nimotuzumab combined with concurrent chemo-radiotherapy improved the ORR, and prolonged PFS and OS in unresectable ESCC patients with a good tolerance.
Collapse
|
62
|
Yuan J, Yu J, Chen D. The Updated Landscape of Tumor Microenvironment and Pre-Metastasis Niches for Radiotherapy Resistant Tumors. Int J Radiat Oncol Biol Phys 2023; 117:S166-S167. [PMID: 37784415 DOI: 10.1016/j.ijrobp.2023.06.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) In the current clinical work, hypo-fractionated radiotherapy (HFRT) and conventional fractionated radiotherapy (CFRT) are considered to be completely different treatments. However, the difference between the HFRT and CFRT in reprogramming the tumor immune microenvironment (TIME) is still inconclusive. Our previous work found that compared with HFRT, CFRT is more inclined to trigger immunosuppressive phenotype, but the underlying mechanism is still unclear. Based on this, we use single-cell mRNA sequencing to describe the landscape of TIME with HFRT and CFRT, and find the key targets or pathways to combine with radiotherapy. MATERIALS/METHODS By simulating the in vivo radiotherapy strategy, we built recurrent murine cell lines mimicking CFRT and HFRT recurrent tumors (CFRT_R and HFRT_R tumors) with small animal radiation research platform (SARRP). RESULTS Based on this unique model, we found that CFRT_R tumors can promote local relapse and lung metastasis significantly compared to HFRT_R tumors. Results of single-cell mRNA sequencing and FCAS also indicate that CFRT_R tumors possess more macrophages in the tumor site and neutrophils in the metastatic site. By using quantitative proteomics of secreted proteins, we prove that CFRT_R tumors secret more Ccl2, S100a11 and Slpi. Mechanically, CFRT_R tumors influence the polarization of M2 TAMs leading to tumor growth through secretion of Ccl2 and S100a11. Meanwhile, CFRT_R tumors also augment the infiltration of neutrophils in the lung through Slpi altering the lung immune landscape to support metastasis. ChIP and EMSA results also reveal that RelB is the core transcription factor of Ccl2, S100a11 and Slpi. Furthermore, local relapse and lung metastasis can be reversed by targeting non-canonical NF-kB pathway. CONCLUSION The effect of CFRT_R and HFRT_R tumors in reprogramming TIME is different, CFRT_R tumors can trigger immunosuppressive phenotype compared to HFRT_R tumors by possessing more M2 TAMs in the tumor site and neutrophils in the metastatic site. The killing function of tumor infiltrated T cells can be inhibited by accumulated M2 TAMs, and abundant neutrophils in lungs contribute to the formation of the pre-metastatic niche. Targeting non-canonical NF-kB pathway can reverse local relapse and lung metastasis in CFRT_R tumors by suppressing Ccl2, S100a11 and Slpi secretion. In short, our study not only deepens the understanding of the immune landscape of CFRT and HFRT recurrence tumors, but also provides a novel therapy of CFRT recurrence patients.
Collapse
|
63
|
Wang S, Wang Y, Ichraf M, Zhou Y, Song Y, Fu X, Liu T, Ma J, Zhuang F, Hu X, Hou J, Yu J, Yang Z, Liu F, Sun Y. Expression of FOXO3 in the skin follicles of goose embryos during embryonic development. Br Poult Sci 2023; 64:586-593. [PMID: 37334805 DOI: 10.1080/00071668.2023.2226078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Accepted: 05/16/2023] [Indexed: 06/21/2023]
Abstract
1. The Forkhead box O3 (FOXO3) transcription factor is a crucial regulator in controlling cell metabolism, proliferation, apoptosis, migration and response to oxidative stress. However, FOXO3 has not previously been studied much in the embryonic skin follicles of geese.2. This study used Zhedong white geese (Anser cygnoides), Jilin white geese (Anser cygnoides) and Hungarian white geese (Anser anser). The feather follicle structure in the dorsal skin during embryonic stages was examined with haematoxylin and eosin (HE) and Pollak staining. The FOXO3 protein content in the embryonic dorsal skin from feather follicles was detected using western blotting and quantitative real-time PCR.3. The mRNA expression level of FOXO3 in the dorsal skin of Jilin white geese was highly expressed on embryonic day 23 (E23; P < 0.01), while mRNA expression of FOXO3 was highly expressed in the feather follicle of Hungarian white geese at E28 (P < 0.01). The expression of FOXO3 protein mainly concentrated in the early embryonic phase among these goose breeds (P < 0.05). This suggested that FOXO3 plays a crucial role in the development and growth of embryonic dorsal skin of feather follicles. The location of the FOXO3 protein was determined using the IHC technique, which further verified the effect of FOXO3 in the dorsal skin for feather follicles during embryogenesis.4. The study demonstrated the differential expression and localisation of the FOXO3 gene among different goose species. It was speculated that the gene could potentially improve goose feather follicle development and feather-related traits and provide a basis for further understanding of FOXO3 function in the dorsal tissue of goose embryos.
Collapse
|
64
|
Li L, Yuan S, Cui J, Yin Y, Song X, Yu J. Verification and Mechanism Exploration of CDK4 Alterations on Influencing Radiotherapy Sensitivity in Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e36. [PMID: 37785238 DOI: 10.1016/j.ijrobp.2023.06.727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) In this study, we aimed to explore the changes of functional phenotype before and after radiotherapy through vitro and vivo experiments. The potential pathway was preliminarily clarified. MATERIALS/METHODS Firstly, the relationships between the prognosis and the expression of CDK4 protein in SCLC patients treated with definitive chemoradiotherapy were explored. Then the stable overexpressed/knockdown CDK4 and negative control transfecting SCLC cell lines were established to monitor the changes of cell proliferation, migration, invasion, apoptosis and cell cycle after increasing radiation doses according to a cell counting kit assay, transwell cell migration and invasion assay, apoptosis cell cycle assay and BALB/c mouse model of subcutaneously transplanted tumor. The potential signal pathways were confirmed via KEGG pathway enrichment analysis and western blot. RESULTS Compared with patients with lower CDK4 protein expression, prognosis of those with high CDK4 protein expression was decreased significantly (p < 0.05). The cell activity, migration and invasion ability of overexpression/knockdown CDK4 and negative control group were all decreased with increasing radiation doses, but the activity, migration and invasion ability of cells with overexpression CDK4 was stronger after same dose X-ray irradiation (p<0.01). For group with knockdown CDK4, it showed lower cell activity, migration and invasion than negative control group. After X-ray irradiation, the apoptotic ratio of all groups increased. And cells with overexpressed CDK4 displayed significantly reduced apoptosis, less G0/G1 phase cells, and improved M phase cells than the control group. In addition, compared with negative control group, gross tumor volume of overexpression CDK4 group decreased much smaller after X-ray irradiation. H1339 cells with overexpression CDK4 and negative control group were sequenced by transcriptomic sequencing before and after radiotherapy. Taken together, differential genes were consistently enriched in MAPK pathway. Western blot showed that, compared with the negative control group, overexpression CDK4 group of H1339 and SW1271 cells after radiotherapy all showed significant changes on pERK proteins in the ERK pathway increased significantly (P<0.001). CONCLUSION In this study, the overexpression/knockdown CDK4 and negative control group were successfully constructed in H1339 and SW1271 cells, revealing the radiotherapy resistance of CDK4 alterations in vitro and in vivo experiment. And CDK4 alterations was shown to promote radiotherapy resistance through phosphorylation of MAPK/ERK signaling pathway in SCLC.
Collapse
|
65
|
Hu X, Zhao M, Xue Z, Zhu Z, Yu J, Yue J. PARP Inhibitor Plus Radiotherapy Reshapes IDH1 Mutation Tumor Immune Suppression Microenvironment Potentiating the Efficiency of Immune Checkpoint Inhibitor. Int J Radiat Oncol Biol Phys 2023; 117:S159. [PMID: 37784398 DOI: 10.1016/j.ijrobp.2023.06.586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Isocitrate dehydrogenase 1 (IDH1) mutations confer gain-of-function activity by converting α-ketoglutarate (α-KG) to the oncometabolite D-2-hydroxyglutarate (D-2HG). IDH mutant tumors have fewer tumor-infiltrating CD8+ T cells and reduced PD-L1 expression compared with their wild type (WT) counterparts. In addition, 2-HG can directly inhibit the killing and proliferative functions of CD8+ T lymphocytes, and suggesting that 2-HG promotes an immunosuppressive TME. Several studies have shown that 2-HG can inhibit homologous recombination (HR) and weaken the DNA damage response (DDR), making them more sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors and radiotherapy (RT). At the same time, RT and PARP inhibition (PARPi) have been considered to be a new direction to stimulate antitumor immunity. Therefore, our study intends to use RT + PARPi to reverse the immunosuppressive microenvironment caused by IDH1 mutations, thereby promoting the therapeutic effect of immune checkpoint inhibitors. MATERIALS/METHODS We compared the immune responses of clinical tissue samples and TCGA data from either IDH1mut or IDH1WT low-grade gliomas. We then established IDH1mut-overexpressing MC38 and GL261 cell lines to determine the antitumor effect of RT + PARPi. Apoptosis and immunogenic death markers were detected by flow cytometry, western blot (WB) and ELISA in these cell lines. Tumor growth and mouse survival curves were observed in both an MC38 subcutaneous and GL261 orthotopic tumor model. Changes in the composition of the immune microenvironment were assessed using flow cytometry. The mechanisms underpinning these compositional shifts were then further interrogated using various techniques, including WB, immunofluorescence, qRT-PCR, CRISPR/Cas9, and CD8+ T cell migration experiments. RESULTS We observed that CD8+ T cell infiltration and expression of the chemokines CXCL10 and CCL5 of CD8+ T cells in IDH1mut tumors were significantly downregulated by immunohistochemistry and TCGA analysis. Gene enrichment analysis using the TCGA database found that IDH1 mutations downregulated interferon (IFN)-related signaling pathways. RT + PARPi induces more DNA damage and actives the CGAS-STING pathway compared with monotherapy, leading to more expression of IFN-β, CXCL10 and CCL5 at mRNA and protein level. In the MC38 subcutaneous tumor model, we found that RT + PARPi increased the infiltration of CD8+ T cells while enhancing the killing function of CD8+ T cells. We observed these same effects in the GL261 orthoma model, as well as increased proliferation function of CD8+ T cells. In addition, RT + PARPi increased the expression of PD-L1 and enhanced the therapeutic effect of immune checkpoint inhibitors. CONCLUSION RT + PARPi reshapes the IDH1mut tumor immune suppression microenvironment, thereby potentiating the antitumor effect and efficiency of immune checkpoint inhibitor.
Collapse
|
66
|
Ma J, Zhang J, Shang S, Wang F, Yu J, Chen D. A Dosimetric Study Indicates the Spinal Cord Irradiation Contributes to Acute Hematologic Toxicities in Non-Small Cell Lung Cancer Patients Receiving Radiotherapy Combined with Immunotherapy. Int J Radiat Oncol Biol Phys 2023; 117:S154-S155. [PMID: 37784388 DOI: 10.1016/j.ijrobp.2023.06.577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To assess the radiation therapy (RT) dose to radiation-associated hematologic toxicities (HTs) in patients with non-small cell lung cancer (NSCLC) after RT combined with immunotherapy. MATERIALS/METHODS Cases of NSCLC treated with RT combined with immunotherapy at Shandong Cancer Hospital in China were identified. The mean dose and the volume of the spinal cord receiving at least 5 to 40 Gy (V5-V40) were retrospectively recorded. Logistic regression was used to estimate associations between grade ≥3 HT (HT3+) and dosimetric/clinical parameters. Receiver operating characteristic analysis was used to determine dosimetric cut-points. RESULTS Ninety-nine patients were analyzed. The majority were male (n = 78, 78.8%) and received chemotherapy (n = 83, 83.9%). All patients received either anti-PD-1 immune checkpoint (n = 89, 89.9%) or anti-PD-L1 immune checkpoint (n = 10, 10.1%) therapy. The rate of HT3+ was 24.2% (n = 24). Spinal cord mean dose, V5 to V40 and BMI parameters associated with HT3+ were included in the multivariate analysis. On multivariate analysis, increasing mean spinal cord dose (per Gy) was associated with higher odds of developing HT3+ (odds ratio 1.053, 95% confidence interval 1.002-1.105, P = .041), as were increasing spinal cord V5 to V20 (As show in the Table below). The optimal cut-points identified were V5 = 52.5%, V10 = 47.5%, V20 = 39.4%, and mean dose = 23.3 Gy. Patients with values above these cut-points had an approximately 2-fold increased risk of HT3+. CONCLUSION We found that mean spinal cord dose and low-dose parameters (V5-V20) were associated with HT3+ in NSCLC patients after RT and immunotherapy. The mean dose of the spinal cord should be kept lower than 23.3 Gy for these patients. These data suggested that efforts to spare doses to the spinal cord might reduce rates of severe HT.
Collapse
|
67
|
Hu X, Han C, Zhang M, Mu Z, Fu Z, Ren J, Qiao K, Jia J, Yu J, Yuan S, Wei Y. Predicting Radiation Esophagitis using 18F-FAPI-04 PET/CT in Patients with LA-ESCC Treated with Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e303-e304. [PMID: 37785107 DOI: 10.1016/j.ijrobp.2023.06.2323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) This prospective study examined whether 18F-FAPI-04 PET/CT can predict the development and severity of radiation esophagitis (RE) in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) treated with concurrent chemoradiotherapy. MATERIALS/METHODS From June 2021 to March 2022, images were prospectively collected from LA-ESCC patients who underwent 18F-FAPI-04 PET/CT examinations before and during radiotherapy. The development of RE was evaluated weekly according to Radiation Therapy Oncology Group criterion. The target-to-background ratio in blood (TBRblood) was analyzed at each time point and correlated with the onset and severity of RE. Factors that predicted RE were identified by multivariate logistic analyses. RESULTS Thirty patients (median age, 66.5 years [interquartile range: 56¨C71 years]; 22 men) were evaluated. Significantly higher TBRblood (during radiotherapy, mean: 3.06 vs 7.11, P = 0.003) and change in TBRblood compared with pre-RT (ΔTBRblood, mean: 0.67 vs 4.81, P = 0.002) were observed in patients with RE than patients without RE. Those with grade 3 RE had a significantly higher TBRblood (during radiotherapy, mean: 4.55 vs 9.66, P = 0.003) and ΔTBRblood (mean: 2.16 vs 7.50, P = 0.003) compared with those with RE CONCLUSION The ΔTBRblood on 18F-FAPI-04 PET/CT may be effective at identifying patients at risk for the development of RE, especially grade 3 RE.
Collapse
|
68
|
Aaij R, Abdelmotteleb ASW, Abellan Beteta C, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Adlarson P, Afsharnia H, Agapopoulou C, Aidala CA, Ajaltouni Z, Akar S, Akiba K, Albicocco P, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alvarez Cartelle P, Amalric R, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson M, Andreianov A, Andreotti M, Andreou D, Ao D, Archilli F, Artamonov A, Artuso M, Aslanides E, Atzeni M, Audurier B, Bachiller Perea IB, Bachmann S, Bachmayer M, Back JJ, Bailly-Reyre A, Baladron Rodriguez P, Balagura V, Baldini W, Baptista de Souza Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga IB, Beiter A, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Benane G, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Bernet Andres S, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhom J, Bian L, Bieker MS, Biesuz NV, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Blago MP, Blake T, Blanc F, Blank JE, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bolognani CS, Bolzonella R, Bondar N, Borgato F, Borghi S, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodzicka J, Brossa Gonzalo A, Brown J, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Cali S, Calvi M, Calvo Gomez M, Campana P, Campora Perez DH, Campoverde Quezada AF, Capelli S, Capriotti L, Carbone A, Cardinale R, Cardini A, Carniti P, Carus L, Casais Vidal A, Caspary R, Casse G, Cattaneo M, Cavallero G, Cavallini V, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chahrour I, Chapman MG, Charles M, Charpentier P, Chavez Barajas CA, Chefdeville M, Chen C, Chen S, Chernov A, Chernyshenko S, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Cid Vidal X, Ciezarek G, Cifra P, Ciullo G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Corredoira I, Corti G, Couturier B, Craik DC, Cruz Torres M, Currie R, Da Silva CL, Dadabaev S, Dai L, Dai X, Dall'Occo E, Dalseno J, D'Ambrosio C, Daniel J, Danilina A, d'Argent P, Davies JE, Davis A, De Aguiar Francisco O, de Boer J, De Bruyn K, De Capua S, De Cian M, De Freitas Carneiro Da Graca U, De Lucia E, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Del Buono L, Delaney B, Dembinski HP, Denysenko V, Deschamps O, Dettori F, Dey B, Di Nezza P, Diachkov I, Didenko S, Dieste Maronas L, Ding S, Dobishuk V, Dolmatov A, Dong C, Donohoe AM, Dordei F, Dos Reis AC, Douglas L, Downes AG, Duda P, Dudek MW, Dufour L, Duk V, Durante P, Duras MM, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eirea Orro C, Eisenhardt S, Ejopu E, Ek-In S, Eklund L, Elashri ME, Ellbracht J, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Fabiano F, Falcao LN, Fan Y, Fang B, Fantini L, Faria M, Farry S, Fazzini D, Felkowski LF, Feo M, Fernandez Gomez M, Fernez AD, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Frontini L, Fu J, Fuehring Q, Fulghesu T, Gabriel E, Galati G, Galati MD, Gallas Torreira A, Galli D, Gambetta S, Gandelman M, Gandini P, Gao HG, Gao Y, Gao Y, Garau M, Garcia Martin LM, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales FA, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironella Gironell P, Giugliano C, Giza MA, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorelov IV, Gotti C, Grabowski JP, Grammatico T, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu AT, Greeven LM, Grieser NA, Grillo L, Gromov S, Gruberg Cazon BR, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Hadjivasiliou C, Haefeli G, Haen C, Haimberger J, Haines SC, Halewood-Leagas T, Halvorsen MM, Hamilton PM, Hammerich J, Han Q, Han X, Hansmann-Menzemer S, Hao L, Harnew N, Harrison T, Hasse C, Hatch M, He J, Heijhoff K, Hemmer FH, Henderson C, Henderson RDL, Hennequin AM, Hennessy K, Henry L, Herd J, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Horswill J, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Iniukhin A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jaimes Elles SJ, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang E, Jiang X, Jiang Y, John M, Johnson D, Jones CR, Jones TP, Joshi SJ, Jost B, Jurik N, Juszczak I, Kandybei S, Kang Y, Karacson M, Karpenkov D, Karpov M, Kautz JW, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Khreich G, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kolk L, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kozachuk A, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kubat J, Kubis S, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kulikova EK, Kupsc A, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Landesa Gomez C, Lane JJ, Lane R, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Lazzaroni M, Lazzeroni C, Le Gac R, Lee SH, Lefèvre R, Leflat A, Legotin S, Lenisa P, Leroy O, Lesiak T, Leverington B, Li A, Li H, Li K, Li P, Li PR, Li S, Li T, Li T, Li Y, Li Z, Liang X, Lin C, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu K, Liu Q, Liu S, Lobo Salvia A, Loi A, Lollini R, Lomba Castro J, Longstaff I, Lopes JH, Lopez Huertas A, López Soliño S, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lusiani A, Lynch K, Lyu XR, Ma R, Maccolini S, Machefert F, Maciuc F, Mackay I, Macko V, Madhan Mohan LR, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Manca G, Mancinelli G, Mancuso C, Manera Escalero R, Manuzzi D, Manzari CA, Marangotto D, Marchand JF, Marconi U, Mariani S, Marin Benito C, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, McGrath TH, McHugh NT, McNab A, McNulty R, Meadows B, Meier G, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Miao D, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Miralles T, Mitchell SE, Mitreska B, Mitzel DS, Modak A, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monk M, Monroy IA, Monteil S, Morello G, Morello MJ, Morgenthaler MP, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muhammad E, Muheim F, Mulder M, Müller K, Murphy CH, Murray D, Murta R, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Neustroev P, Newcombe R, Nicolini J, Nicotra D, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Novoa Fernandez J, Nowak GN, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, Okamura S, Oldeman R, Oliva F, Onderwater CJG, O'Neil RH, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Ozcelik O, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Panshin G, Paolucci L, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Pereiro Castro A, Perret P, Petridis K, Petrolini A, Petrucci S, Petruzzo M, Pham H, Philippov A, Piandani R, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pisani F, Pizzichemi M, Placinta V, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Punzi G, Qi HR, Qian W, Qin N, Qu S, Quagliani R, Raab NV, Rachwal B, Rademacker JH, Rajagopalan R, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Rebollo De Miguel M, Redi F, Reich J, Reiss F, Remon Alepuz C, Ren Z, Resmi PK, Ribatti R, Ricci AM, Ricciardi S, Richardson K, Richardson-Slipper M, Rinnert K, Robbe P, Robertson G, Rodrigues E, Rodriguez Fernandez E, Rodriguez Lopez JA, Rodriguez Rodriguez E, Rolf DL, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Fernandez RA, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva JJ, Sagidova N, Sahoo N, Saitta B, Salomoni M, Sanchez Gras C, Sanderswood I, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead LG, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sciuccati A, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Sheng S, Shevchenko V, Shi B, Shields EB, Shimizu Y, Shmanin E, Shorkin R, Shupperd JD, Siddi BG, Silva Coutinho R, Simi G, Simone S, Singla M, Skidmore N, Skuza R, Skwarnicki T, Slater MW, Smallwood JC, Smeaton JG, Smith E, Smith K, Smith M, Snoch A, Soares Lavra L, Sokoloff MD, Soler FJP, Solomin A, Solovev A, Solovyev I, Song R, Souza De Almeida FL, Souza De Paula B, Spaan B, Spadaro Norella E, Spedicato E, Spiridenkov E, Spradlin P, Sriskaran V, Stagni F, Stahl M, Stahl S, Stanislaus S, Stein EN, Steinkamp O, Stenyakin O, Stevens H, Strekalina D, Su YS, Suljik F, Sun J, Sun L, Sun Y, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Tan Y, Taneja S, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tilquin H, Tisserand V, T'Jampens S, Tobin M, Tomassetti L, Tonani G, Tong X, Torres Machado D, Tou DY, Trippl C, Tuci G, Tuning N, Ukleja A, Unverzagt DJ, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, Van Dijk M, Van Hecke H, van Herwijnen E, Van Hulse CB, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Vilasis-Cardona X, Vilella Figueras E, Villa A, Vincent P, Volle FC, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Vrahas C, Walsh J, Walton EJ, Wan G, Wang C, Wang G, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang X, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Websdale D, Wei Y, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson MK, Williams I, Williams M, Williams MRJ, Williams R, Wilson FF, Wislicki W, Witek M, Witola L, Wong CP, Wormser G, Wotton SA, Wu H, Wu J, Wyllie K, Xiang Z, Xie Y, Xu A, Xu J, Xu L, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang X, Yang Y, Yang Z, Yang Z, Yeomans LE, Yeroshenko V, Yeung H, Yin H, Yu J, Yuan X, Zaffaroni E, Zavertyaev M, Zdybal M, Zeng M, Zhang C, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zhao Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zou Q, Zucchelli S, Zuliani D, Zunica G. Observation of New Ω_{c}^{0} States Decaying to the Ξ_{c}^{+}K^{-} Final State. PHYSICAL REVIEW LETTERS 2023; 131:131902. [PMID: 37831985 DOI: 10.1103/physrevlett.131.131902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 04/26/2023] [Accepted: 06/26/2023] [Indexed: 10/15/2023]
Abstract
Two new excited states, Ω_{c}(3185)^{0} and Ω_{c}(3327)^{0}, are observed in the Ξ_{c}^{+}K^{-} invariant-mass spectrum using proton-proton collision data collected by the LHCb experiment, corresponding to an integrated luminosity of 9 fb^{-1}. Five previously observed excited Ω_{c}^{0} states are confirmed, namely Ω_{c}(3000)^{0}, Ω_{c}(3050)^{0}, Ω_{c}(3065)^{0}, Ω_{c}(3090)^{0}, and Ω_{c}(3119)^{0}. The masses and widths of these seven states are measured with the highest precision to date.
Collapse
|
69
|
Aaij R, Abdelmotteleb ASW, Abellan Beteta C, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Adlarson P, Afsharnia H, Agapopoulou C, Aidala CA, Ajaltouni Z, Akar S, Akiba K, Albicocco P, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alvarez Cartelle P, Amalric R, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson M, Andreianov A, Andreotti M, Andreou D, Ao D, Archilli F, Artamonov A, Artuso M, Aslanides E, Atzeni M, Audurier B, Bachiller Perea I, Bachmann S, Bachmayer M, Back JJ, Bailly-Reyre A, Baladron Rodriguez P, Balagura V, Baldini W, Baptista de Souza Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga IB, Beiter A, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Benane G, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Bernet Andres S, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Biesuz NV, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Blago MP, Blake T, Blanc F, Blank JE, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bolognani CS, Bolzonella R, Bondar N, Borgato F, Borghi S, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodzicka J, Brossa Gonzalo A, Brown J, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Cali S, Calvi M, Calvo Gomez M, Campana P, Campora Perez DH, Campoverde Quezada AF, Capelli S, Capriotti L, Carbone A, Cardinale R, Cardini A, Carniti P, Carus L, Casais Vidal A, Caspary R, Casse G, Cattaneo M, Cavallero G, Cavallini V, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chahrour I, Chapman MG, Charles M, Charpentier P, Chavez Barajas CA, Chefdeville M, Chen C, Chen S, Chernov A, Chernyshenko S, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Cid Vidal X, Ciezarek G, Cifra P, Ciullo G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Corredoira I, Corti G, Couturier B, Craik DC, Cruz Torres M, Currie R, Da Silva CL, Dadabaev S, Dai L, Dai X, Dall'Occo E, Dalseno J, D'Ambrosio C, Daniel J, Danilina A, d'Argent P, Davies JE, Davis A, De Aguiar Francisco O, de Boer J, De Bruyn K, De Capua S, De Cian M, De Freitas Carneiro Da Graca U, De Lucia E, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Del Buono L, Delaney B, Dembinski HP, Denysenko V, Deschamps O, Dettori F, Dey B, Di Nezza P, Diachkov I, Didenko S, Dieste Maronas L, Ding S, Dobishuk V, Dolmatov A, Dong C, Donohoe AM, Dordei F, Dos Reis AC, Douglas L, Downes AG, Duda P, Dudek MW, Dufour L, Duk V, Durante P, Duras MM, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eirea Orro C, Eisenhardt S, Ejopu E, Ek-In S, Eklund L, Elashri M, Ellbracht J, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Fabiano F, Falcao LN, Fan Y, Fang B, Fantini L, Faria M, Farry S, Fazzini D, Felkowski L, Feo M, Fernandez Gomez M, Fernez AD, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Frontini L, Fu J, Fuehring Q, Fulghesu T, Gabriel E, Galati G, Galati MD, Gallas Torreira A, Galli D, Gambetta S, Gandelman M, Gandini P, Gao Y, Gao Y, Garau M, Garcia Martin LM, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales FA, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironella Gironell P, Giugliano C, Giza MA, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorelov IV, Gotti C, Grabowski JP, Grammatico T, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu AT, Greeven LM, Grieser NA, Grillo L, Gromov S, Gruberg Cazon BR, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Hadjivasiliou C, Haefeli G, Haen C, Haimberger J, Haines SC, Halewood-Leagas T, Halvorsen MM, Hamilton PM, Hammerich J, Han Q, Han X, Hansen EB, Hansmann-Menzemer S, Hao L, Harnew N, Harrison T, Hasse C, Hatch M, He J, Heijhoff K, Hemmer FH, Henderson C, Henderson RDL, Hennequin AM, Hennessy K, Henry L, Herd J, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Horswill J, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Iniukhin A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jaimes Elles SJ, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang E, Jiang X, Jiang Y, John M, Johnson D, Jones CR, Jones TP, Jost B, Jurik N, Juszczak I, Kandybei S, Kang Y, Karacson M, Karpenkov D, Karpov M, Kautz JW, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Khreich G, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kolk L, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kozachuk A, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kubat J, Kubis S, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kulikova E, Kupsc A, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Landesa Gomez C, Lane JJ, Lane R, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Lazzaroni M, Le Gac R, Lee SH, Lefèvre R, Leflat A, Legotin S, Lenisa P, Leroy O, Lesiak T, Leverington B, Li A, Li H, Li K, Li P, Li PR, Li S, Li T, Li T, Li Y, Li Z, Liang X, Lin C, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu Q, Liu S, Lobo Salvia A, Loi A, Lollini R, Lomba Castro J, Longstaff I, Lopes JH, Lopez Huertas A, López Soliño S, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lusiani A, Lynch K, Lyu XR, Ma R, Maccolini S, Machefert F, Maciuc F, Mackay I, Macko V, Madhan Mohan LR, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Manca G, Mancinelli G, Mancuso C, Manera Escalero R, Manuzzi D, Manzari CA, Marangotto D, Marchand JF, Marconi U, Mariani S, Marin Benito C, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, McGrath TH, McHugh NT, McNab A, McNulty R, Mead JV, Meadows B, Meier G, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Miao D, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Miralles T, Mitchell SE, Mitreska B, Mitzel DS, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monk M, Monroy IA, Monteil S, Morello G, Morello MJ, Morgenthaler MP, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muhammad E, Muheim F, Mulder M, Müller K, Murphy CH, Murray D, Murta R, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Neustroev P, Newcombe R, Nicolini J, Nicotra D, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Novoa Fernandez J, Nowak G, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, Okamura S, Oldeman R, Oliva F, Onderwater CJG, O'Neil RH, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Ozcelik O, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Paolucci L, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Pereiro Castro A, Perret P, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pham H, Philippov A, Piandani R, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pisani F, Pizzichemi M, Placinta V, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Punzi G, Qi HR, Qian W, Qin N, Qu S, Quagliani R, Raab NV, Rachwal B, Rademacker JH, Rajagopalan R, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Rebollo De Miguel M, Redi F, Reich J, Reiss F, Remon Alepuz C, Ren Z, Resmi PK, Ribatti R, Ricci AM, Ricciardi S, Richardson K, Richardson-Slipper M, Rinnert K, Robbe P, Robertson G, Rodrigues AB, Rodrigues E, Rodriguez Fernandez E, Rodriguez Lopez JA, Rodriguez Rodriguez E, Rolf DL, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Fernandez RA, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva JJ, Sagidova N, Sahoo N, Saitta B, Salomoni M, Sanchez Gras C, Sanderswood I, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead LG, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sciuccati A, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Sheng S, Shevchenko V, Shi B, Shields EB, Shimizu Y, Shmanin E, Shorkin R, Shupperd JD, Siddi BG, Silva Coutinho R, Simi G, Simone S, Singla M, Skidmore N, Skuza R, Skwarnicki T, Slater MW, Smallwood JC, Smeaton JG, Smith E, Smith K, Smith M, Snoch A, Soares Lavra L, Sokoloff MD, Soler FJP, Solomin A, Solovev A, Solovyev I, Song R, Souza De Almeida FL, Souza De Paula B, Spaan B, Spadaro Norella E, Spedicato E, Spiridenkov E, Spradlin P, Sriskaran V, Stagni F, Stahl M, Stahl S, Stanislaus S, Stein EN, Steinkamp O, Stenyakin O, Stevens H, Stone S, Strekalina D, Su Y, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Tan Y, Taneja S, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tilquin H, Tisserand V, T'Jampens S, Tobin M, Tomassetti L, Tonani G, Tong X, Torres Machado D, Tou DY, Trilov SM, Trippl C, Tuci G, Tuning N, Ukleja A, Unverzagt DJ, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, Van Dijk M, Van Hecke H, van Herwijnen E, Van Hulse CB, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Vilasis-Cardona X, Vilella Figueras E, Villa A, Vincent P, Volle FC, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Vrahas C, Walsh J, Walton EJ, Wan G, Wang C, Wang G, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang X, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Websdale D, Wei Y, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson MK, Williams I, Williams M, Williams MRJ, Williams R, Wilson FF, Wislicki W, Witek M, Witola L, Wong CP, Wormser G, Wotton SA, Wu H, Wu J, Wyllie K, Xiang Z, Xie Y, Xu A, Xu J, Xu L, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang X, Yang Y, Yang Z, Yang Z, Yeomans LE, Yeroshenko V, Yeung H, Yin H, Yu J, Yuan X, Zaffaroni E, Zavertyaev M, Zdybal M, Zeng M, Zhang C, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zhao Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zou Q, Zucchelli S, Zuliani D, Zunica G. Evidence of a J/ψK_{S}^{0} Structure in B^{0}→J/ψϕK_{S}^{0} Decays. PHYSICAL REVIEW LETTERS 2023; 131:131901. [PMID: 37832008 DOI: 10.1103/physrevlett.131.131901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Accepted: 03/21/2023] [Indexed: 10/15/2023]
Abstract
An amplitude analysis of B^{0}→J/ψϕK_{S}^{0} decays is performed using proton-proton collision data, corresponding to an integrated luminosity of 9 fb^{-1}, collected with the LHCb detector at center-of-mass energies of 7, 8, and 13 TeV. Evidence with a significance of 4.0 standard deviations of a structure in the J/ψK_{S}^{0} system, named T_{ψs1}^{θ}(4000)^{0}, is seen, with its mass and width measured to be 3991_{-10}^{+12} _{-17}^{+9} MeV/c^{2} and 105_{-25}^{+29} _{-23}^{+17} MeV, respectively, where the first uncertainty is statistical and the second systematic. The T_{ψs1}^{θ}(4000)^{0} state is likely to be the isospin partner of the T_{ψs1}^{θ}(4000)^{+} state, previously observed in the J/ψK^{+} system of the B^{+}→J/ψϕK^{+} decay. When isospin symmetry for the charged and neutral T_{ψs1}^{θ}(4000) states is assumed, the signal significance increases to 5.4 standard deviations.
Collapse
|
70
|
Li XY, Liu SH, Liu C, Zu HM, Guo XQ, Xiang HL, Huang Y, Yan ZL, Li YJ, Sun J, Song RX, Yan JQ, Ye Q, Liu F, Huang L, Meng FP, Zhang XN, Yang SS, Hu SJ, Ruan JG, Li YL, Wang NN, Cui HP, Wang YM, Lei C, Wang QH, Tian HL, Qu ZS, Yuan M, Shi RC, Yang XT, Jin D, Su D, Liu YJ, Chen Y, Xia YX, Li YZ, Yang QH, Li H, Zhao XL, Tian ZM, Yu HJ, Zhang XJ, Wu CX, Wu ZJ, Li SS, Shen Q, Liu XM, Hu JP, Wu MQ, Dang T, Wang J, Meng XM, Wang HY, Jiang ZY, Liu YY, Liu Y, Qu SX, Tao H, Yan DM, Liu J, Fu W, Yu J, Wang FS, Qi XL, Fu JL. [Impact of different diagnostic criteria for assessing mild micro-hepatic encephalopathy in liver cirrhosis: an analysis based on a prospective, multicenter, real-world study]. ZHONGHUA GAN ZANG BING ZA ZHI = ZHONGHUA GANZANGBING ZAZHI = CHINESE JOURNAL OF HEPATOLOGY 2023; 31:961-968. [PMID: 37872092 DOI: 10.3760/cma.j.cn501113-20220602-00298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/25/2023]
Abstract
Objective: To compare the differences in the prevalence of mild micro-hepatic encephalopathy (MHE) among patients with cirrhosis by using the psychometric hepatic encephalopathy score (PHES) and the Stroop smartphone application (Encephal App) test. Methods: This prospective, multi-center, real-world study was initiated by the National Clinical Medical Research Center for Infectious Diseases and the Portal Hypertension Alliance and registered with International ClinicalTrials.gov (NCT05140837). 354 cases of cirrhosis were enrolled in 19 hospitals across the country. PHES (including digital connection tests A and B, digital symbol tests, trajectory drawing tests, and serial management tests) and the Stroop test were conducted in all of them. PHES was differentiated using standard diagnostic criteria established by the two studies in China and South Korea. The Stroop test was evaluated based on the criteria of the research and development team. The impact of different diagnostic standards or methods on the incidence of MHE in patients with cirrhosis was analyzed. Data between groups were differentiated using the t-test, Mann-Whitney U test, and χ (2) test. A kappa test was used to compare the consistency between groups. Results: After PHES, the prevalence of MHE among 354 cases of cirrhosis was 78.53% and 15.25%, respectively, based on Chinese research standards and Korean research normal value standards. However, the prevalence of MHE was 56.78% based on the Stroop test, and the differences in pairwise comparisons among the three groups were statistically significant (kappa = -0.064, P < 0.001). Stratified analysis revealed that the MHE prevalence in three groups of patients with Child-Pugh classes A, B, and C was 74.14%, 83.33%, and 88.24%, respectively, according to the normal value standards of Chinese researchers, while the MHE prevalence rates in three groups of patients with Child-Pugh classes A, B, and C were 8.29%, 23.53%, and 38.24%, respectively, according to the normal value standards of Korean researchers. Furthermore, the prevalence rates of MHE in the three groups of patients with Child-Pugh grades A, B, and C were 52.68%, 58.82%, and 73.53%, respectively, according to the Stroop test standard. However, among the results of each diagnostic standard, the prevalence of MHE showed an increasing trend with an increasing Child-Pugh grade. Further comparison demonstrated that the scores obtained by the number connection test A and the number symbol test were consistent according to the normal value standards of the two studies in China and South Korea (Z = -0.982, -1.702; P = 0.326, 0.089), while the other three sub-tests had significant differences (P < 0.001). Conclusion: The prevalence rate of MHE in the cirrhotic population is high, but the prevalence of MHE obtained by using different diagnostic criteria or methods varies greatly. Therefore, in line with the current changes in demographics and disease spectrum, it is necessary to enroll a larger sample size of a healthy population as a control. Moreover, the establishment of more reliable diagnostic scoring criteria will serve as a basis for obtaining accurate MHE incidence and formulating diagnosis and treatment strategies in cirrhotic populations.
Collapse
|
71
|
Aaij R, Abdelmotteleb ASW, Abellan Beteta C, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Adlarson P, Afsharnia H, Agapopoulou C, Aidala CA, Ajaltouni Z, Akar S, Akiba K, Albicocco P, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alvarez Cartelle P, Amalric R, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson M, Andreianov A, Andreotti M, Andreou D, Ao D, Archilli F, Artamonov A, Artuso M, Aslanides E, Atzeni M, Audurier B, Bachiller Perea IB, Bachmann S, Bachmayer M, Back JJ, Bailly-Reyre A, Baladron Rodriguez P, Balagura V, Baldini W, Baptista de Souza Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga IB, Beiter A, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Benane G, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Bernet Andres S, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Biesuz NV, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Blago MP, Blake T, Blanc F, Blank JE, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bolognani CS, Bolzonella R, Bondar N, Borgato F, Borghi S, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodzicka J, Brossa Gonzalo A, Brown J, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Cali S, Calvi M, Calvo Gomez M, Campana P, Campora Perez DH, Campoverde Quezada AF, Capelli S, Capriotti L, Carbone A, Cardinale R, Cardini A, Carniti P, Carus L, Casais Vidal A, Caspary R, Casse G, Cattaneo M, Cavallero G, Cavallini V, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chahrour I, Chapman MG, Charles M, Charpentier P, Chavez Barajas CA, Chefdeville M, Chen C, Chen S, Chernov A, Chernyshenko S, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Cid Vidal X, Ciezarek G, Cifra P, Ciullo G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Corredoira I, Corti G, Couturier B, Craik DC, Cruz Torres M, Currie R, Da Silva CL, Dadabaev S, Dai L, Dai X, Dall'Occo E, Dalseno J, D'Ambrosio C, Daniel J, Danilina A, d'Argent P, Davies JE, Davis A, De Aguiar Francisco O, de Boer J, De Bruyn K, De Capua S, De Cian M, De Freitas Carneiro Da Graca U, De Lucia E, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Del Buono L, Delaney B, Dembinski HP, Denysenko V, Deschamps O, Dettori F, Dey B, Di Nezza P, Diachkov I, Didenko S, Dieste Maronas L, Ding S, Dobishuk V, Dolmatov A, Dong C, Donohoe AM, Dordei F, Dos Reis AC, Douglas L, Downes AG, Duda P, Dudek MW, Dufour L, Duk V, Durante P, Duras MM, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eirea Orro C, Eisenhardt S, Ejopu E, Ek-In S, Eklund L, Elashri ME, Ellbracht J, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Fabiano F, Falcao LN, Fan Y, Fang B, Fantini L, Faria M, Farry S, Fazzini D, Felkowski LF, Feo M, Fernandez Gomez M, Fernez AD, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Frontini L, Fu J, Fuehring Q, Fulghesu T, Gabriel E, Galati G, Galati MD, Gallas Torreira A, Galli D, Gambetta S, Gandelman M, Gandini P, Gao Y, Gao Y, Garau M, Garcia Martin LM, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales FA, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironella Gironell P, Giugliano C, Giza MA, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorelov IV, Gotti C, Grabowski JP, Grammatico T, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu AT, Greeven LM, Grieser NA, Grillo L, Gromov S, Gruberg Cazon BR, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Hadjivasiliou C, Haefeli G, Haen C, Haimberger J, Haines SC, Halewood-Leagas T, Halvorsen MM, Hamilton PM, Hammerich J, Han Q, Han X, Hansen EB, Hansmann-Menzemer S, Hao L, Harnew N, Harrison T, Hasse C, Hatch M, He J, Heijhoff K, Hemmer FH, Henderson C, Henderson RDL, Hennequin AM, Hennessy K, Henry L, Herd J, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Horswill J, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Iniukhin A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jaimes Elles SJ, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang E, Jiang X, Jiang Y, John M, Johnson D, Jones CR, Jones TP, Jost B, Jurik N, Juszczak I, Kandybei S, Kang Y, Karacson M, Karpenkov D, Karpov M, Kautz JW, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Khreich G, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kolk L, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kozachuk A, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kubat J, Kubis S, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kulikova EK, Kupsc A, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Landesa Gomez C, Lane JJ, Lane R, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Lazzaroni M, Le Gac R, Lee SH, Lefèvre R, Leflat A, Legotin S, Lenisa P, Leroy O, Lesiak T, Leverington B, Li A, Li H, Li K, Li P, Li PR, Li S, Li T, Li T, Li Y, Li Z, Liang X, Lin C, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu Q, Liu S, Lobo Salvia A, Loi A, Lollini R, Lomba Castro J, Longstaff I, Lopes JH, Lopez Huertas A, López Soliño S, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lusiani A, Lynch K, Lyu XR, Ma R, Maccolini S, Machefert F, Maciuc F, Mackay I, Macko V, Madhan Mohan LR, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Manca G, Mancinelli G, Mancuso C, Manera Escalero R, Manuzzi D, Manzari CA, Marangotto D, Marchand JF, Marconi U, Mariani S, Marin Benito C, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, McGrath TH, McHugh NT, McNab A, McNulty R, Mead JV, Meadows B, Meier G, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Miao D, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Miralles T, Mitchell SE, Mitreska B, Mitzel DS, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monk M, Monroy IA, Monteil S, Morello G, Morello MJ, Morgenthaler MP, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muhammad E, Muheim F, Mulder M, Müller K, Murphy CH, Murray D, Murta R, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Neustroev P, Newcombe R, Nicolini J, Nicotra D, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Novoa Fernandez J, Nowak GN, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, Okamura S, Oldeman R, Oliva F, Onderwater CJG, O'Neil RH, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Ozcelik O, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Paolucci L, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Pereiro Castro A, Perret P, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pham H, Philippov A, Piandani R, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pisani F, Pizzichemi M, Placinta V, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Punzi G, Qi HR, Qian W, Qin N, Qu S, Quagliani R, Raab NV, Rachwal B, Rademacker JH, Rajagopalan R, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Rebollo De Miguel M, Redi F, Reich J, Reiss F, Remon Alepuz C, Ren Z, Resmi PK, Ribatti R, Ricci AM, Ricciardi S, Richardson K, Richardson-Slipper M, Rinnert K, Robbe P, Robertson G, Rodrigues AB, Rodrigues E, Rodriguez Fernandez E, Rodriguez Lopez JA, Rodriguez Rodriguez E, Rolf DL, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Fernandez RA, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva JJ, Sagidova N, Sahoo N, Saitta B, Salomoni M, Sanchez Gras C, Sanderswood I, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead LG, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sciuccati A, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Sheng S, Shevchenko V, Shi B, Shields EB, Shimizu Y, Shmanin E, Shorkin R, Shupperd JD, Siddi BG, Silva Coutinho R, Simi G, Simone S, Singla M, Skidmore N, Skuza R, Skwarnicki T, Slater MW, Smallwood JC, Smeaton JG, Smith E, Smith K, Smith M, Snoch A, Soares Lavra L, Sokoloff MD, Soler FJP, Solomin A, Solovev A, Solovyev I, Song R, Souza De Almeida FL, Souza De Paula B, Spaan B, Spadaro Norella E, Spedicato E, Spiridenkov E, Spradlin P, Sriskaran V, Stagni F, Stahl M, Stahl S, Stanislaus S, Stein EN, Steinkamp O, Stenyakin O, Stevens H, Stone S, Strekalina D, Su YS, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Tan Y, Taneja S, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tilquin H, Tisserand V, T'Jampens S, Tobin M, Tomassetti L, Tonani G, Tong X, Torres Machado D, Tou DY, Trilov SM, Trippl C, Tuci G, Tuning N, Ukleja A, Unverzagt DJ, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, Van Dijk M, Van Hecke H, van Herwijnen E, Van Hulse CB, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Vilasis-Cardona X, Vilella Figueras E, Villa A, Vincent P, Volle FC, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Vrahas C, Walsh J, Walton EJ, Wan G, Wang C, Wang G, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang X, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Websdale D, Wei Y, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson MK, Williams I, Williams M, Williams MRJ, Williams R, Wilson FF, Wislicki W, Witek M, Witola L, Wong CP, Wormser G, Wotton SA, Wu H, Wu J, Wyllie K, Xiang Z, Xie Y, Xu A, Xu J, Xu L, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang X, Yang Y, Yang Z, Yang Z, Yeomans LE, Yeroshenko V, Yeung H, Yin H, Yu J, Yuan X, Zaffaroni E, Zavertyaev M, Zdybal M, Zeng M, Zhang C, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zhao Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zou Q, Zucchelli S, Zuliani D, Zunica G. Measurement of the Ratios of Branching Fractions R(D^{*}) and R(D^{0}). PHYSICAL REVIEW LETTERS 2023; 131:111802. [PMID: 37774262 DOI: 10.1103/physrevlett.131.111802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 04/18/2023] [Accepted: 06/29/2023] [Indexed: 10/01/2023]
Abstract
The ratios of branching fractions R(D^{*})≡B(B[over ¯]→D^{*}τ^{-}ν[over ¯]_{τ})/B(B[over ¯]→D^{*}μ^{-}ν[over ¯]_{μ}) and R(D^{0})≡B(B^{-}→D^{0}τ^{-}ν[over ¯]_{τ})/B(B^{-}→D^{0}μ^{-}ν[over ¯]_{μ}) are measured, assuming isospin symmetry, using a sample of proton-proton collision data corresponding to 3.0 fb^{-1} of integrated luminosity recorded by the LHCb experiment during 2011 and 2012. The tau lepton is identified in the decay mode τ^{-}→μ^{-}ν_{τ}ν[over ¯]_{μ}. The measured values are R(D^{*})=0.281±0.018±0.024 and R(D^{0})=0.441±0.060±0.066, where the first uncertainty is statistical and the second is systematic. The correlation between these measurements is ρ=-0.43. The results are consistent with the current average of these quantities and are at a combined 1.9 standard deviations from the predictions based on lepton flavor universality in the standard model.
Collapse
|
72
|
Yu J, Zhao SS, Chen X, Qiao C, Wang R, Li JY, Wu YJ. [The value of CD200 in differential diagnosis of classic hairy cell leukemia and variant hairy cell leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2023; 44:775-779. [PMID: 38049324 PMCID: PMC10630581 DOI: 10.3760/cma.j.issn.0253-2727.2023.09.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Indexed: 12/06/2023]
|
73
|
Wang J, Yu J, Huang X. Pellagra and peripheral neuropathy secondary to tuberculosis treatment. QJM 2023; 116:696-698. [PMID: 37129558 DOI: 10.1093/qjmed/hcad077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Indexed: 05/03/2023] Open
|
74
|
Aaij R, Abdelmotteleb ASW, Abellan Beteta C, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Afsharnia H, Agapopoulou C, Aidala CA, Aiola S, Ajaltouni Z, Akar S, Akiba K, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alvarez Cartelle P, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson M, Andreianov A, Andreotti M, Andreou D, Ao D, Archilli F, Artamonov A, Artuso M, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back JJ, Bailly-Reyre A, Baladron Rodriguez P, Balagura V, Baldini W, Baptista de Souza Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga IB, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Biesuz NV, Bifani S, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Blago MP, Blake T, Blanc F, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bondar N, Borghi S, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodzicka J, Brossa Gonzalo A, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Cali S, Calladine R, Calvi M, Calvo Gomez M, Camargo Magalhaes P, Campana P, Campora Perez DH, Campoverde Quezada AF, Capelli S, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carli I, Carniti P, Carus L, Casais Vidal A, Caspary R, Casse G, Cattaneo M, Cavallero G, Cavallini V, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chapman MG, Charles M, Charpentier P, Chavez Barajas CA, Chefdeville M, Chen C, Chen S, Chernov A, Chernyshenko S, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Cid Vidal X, Ciezarek G, Ciullo G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Coombs G, Corredoira I, Corti G, Couturier B, Craik DC, Crkovská J, Cruz Torres M, Currie R, Da Silva CL, Dadabaev S, Dai L, Dall'Occo E, Dalseno J, D'Ambrosio C, Danilina A, d'Argent P, Davies JE, Davis A, De Aguiar Francisco O, de Boer J, De Bruyn K, De Capua S, De Cian M, De Freitas Carneiro Da Graca U, De Lucia E, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Del Buono L, Delaney B, Dembinski HP, Denysenko V, Deschamps O, Dettori F, Dey B, Di Cicco A, Di Nezza P, Didenko S, Dieste Maronas L, Ding S, Dobishuk V, Dolmatov A, Dong C, Donohoe AM, Dordei F, Dos Reis AC, Douglas L, Downes AG, Dudek MW, Dufour L, Duk V, Durante P, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eisenhardt S, Ek-In S, Eklund L, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Falcao LN, Fan Y, Fang B, Farry S, Fazzini D, Feo M, Fernez AD, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Fu J, Fuehring Q, Gabriel E, Galati G, Gallas Torreira A, Galli D, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Garau M, Garcia Martin LM, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales FA, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironella Gironell P, Giugliano C, Giza MA, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorelov IV, Gotti C, Grabowski JP, Grammatico T, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu AT, Greeven LM, Grieser NA, Grillo L, Gromov S, Gruberg Cazon BR, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Haefeli G, Haen C, Haimberger J, Haines SC, Halewood-Leagas T, Halvorsen MM, Hamilton PM, Hammerich J, Han Q, Han X, Hansen EB, Hansmann-Menzemer S, Hao L, Harnew N, Harrison T, Hasse C, Hatch M, He J, Heijhoff K, Heinicke K, Henderson RDL, Hennequin AM, Hennessy K, Henry L, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Iniukhin A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jaimes Elles SJ, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang X, John M, Johnson D, Jones CR, Jones TP, Jost B, Jurik N, Juszczak I, Kandybei S, Kang Y, Karacson M, Karpenkov D, Karpov M, Kautz JW, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kozachuk A, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kubat J, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kunde GJ, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Lane JJ, Lane R, Lanfranchi G, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Lazzaroni M, Le Gac R, Lee SH, Lefèvre R, Leflat A, Legotin S, Lenisa P, Leroy O, Lesiak T, Leverington B, Li H, Li K, Li P, Li S, Li Y, Li Z, Liang X, Lin C, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu Q, Liu S, Lobo Salvia A, Loi A, Lollini R, Lomba Castro J, Longstaff I, Lopes JH, López Soliño S, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lusiani A, Lynch K, Lyu XR, Ma L, Ma R, Maccolini S, Machefert F, Maciuc F, Macko V, Mackowiak P, Maddrell-Mander S, Madhan Mohan LR, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Malygina H, Manca G, Mancinelli G, Manuzzi D, Manzari CA, Marangotto D, Marchand JF, Marconi U, Mariani S, Marin Benito C, Marinangeli M, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, McGrath TH, McHugh NT, McNab A, McNulty R, Mead JV, Meadows B, Meier G, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Mitchell SE, Mitreska B, Mitzel DS, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monroy IA, Monteil S, Morandin M, Morello G, Morello MJ, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muheim F, Mulder M, Müller K, Murphy CH, Murray D, Murta R, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Neustroev P, Newcombe R, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, O'Hanlon DP, Okamura S, Oldeman R, Oliva F, Olivares ME, Onderwater CJG, O'Neil RH, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Ozcelik O, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pearce A, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Pereiro Castro A, Perret P, Petric M, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pham H, Philippov A, Piandani R, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pisani F, Pizzichemi M, Placinta V, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poliakova M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Popov S, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Punzi G, Qi HR, Qian W, Qin N, Qu S, Quagliani R, Raab NV, Rabadan Trejo RI, Rachwal B, Rademacker JH, Rajagopalan R, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Rebollo De Miguel M, Redi F, Reiss F, Remon Alepuz C, Ren Z, Renaudin V, Resmi PK, Ribatti R, Ricci AM, Ricciardi S, Rinnert K, Robbe P, Robertson G, Rodrigues AB, Rodrigues E, Rodriguez Lopez JA, Rodriguez Rodriguez E, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Fernandez RA, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva JJ, Sagidova N, Sahoo N, Saitta B, Salomoni M, Sanchez Gras C, Sanderswood I, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead LG, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sciuccati A, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Sheng S, Shevchenko V, Shields EB, Shimizu Y, Shmanin E, Shupperd JD, Siddi BG, Silva Coutinho R, Simi G, Simone S, Singla M, Skidmore N, Skuza R, Skwarnicki T, Slater MW, Slazyk I, Smallwood JC, Smeaton JG, Smith E, Smith M, Snoch A, Soares Lavra L, Sokoloff MD, Soler FJP, Solomin A, Solovev A, Solovyev I, Souza De Almeida FL, Souza De Paula B, Spaan B, Spadaro Norella E, Spiridenkov E, Spradlin P, Sriskaran V, Stagni F, Stahl M, Stahl S, Stanislaus S, Steinkamp O, Stenyakin O, Stevens H, Stone S, Strekalina D, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Taneja S, Tanner AR, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tilquin H, Tisserand V, T'Jampens S, Tobin M, Tomassetti L, Tonani G, Tong X, Torres Machado D, Tou DY, Trifonova E, Trilov SM, Trippl C, Tuci G, Tully A, Tuning N, Ukleja A, Unverzagt DJ, Ursov E, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, van Beuzekom M, Van Dijk M, Van Hecke H, van Herwijnen E, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Vilasis-Cardona X, Vilella Figueras E, Villa A, Vincent P, Volle FC, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Waldi R, Walsh J, Wang C, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Websdale D, Weisser C, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson MK, Williams I, Williams M, Williams MRJ, Williams R, Wilson FF, Wislicki W, Witek M, Witola L, Wong CP, Wormser G, Wotton SA, Wu H, Wyllie K, Xiang Z, Xiao D, Xie Y, Xu A, Xu J, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang Y, Yang Z, Yang Z, Yeomans LE, Yin H, Yu J, Yuan X, Zaffaroni E, Zavertyaev M, Zdybal M, Zenaiev O, Zeng M, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zou Q, Zucchelli S, Zuliani D, Zunica G. Measurement of the Prompt D^{0} Nuclear Modification Factor in p-Pb Collisions at sqrt[s_{NN}]=8.16 TeV. PHYSICAL REVIEW LETTERS 2023; 131:102301. [PMID: 37739372 DOI: 10.1103/physrevlett.131.102301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Accepted: 02/24/2023] [Indexed: 09/24/2023]
Abstract
The production of prompt D^{0} mesons in proton-lead collisions in both the forward and backward rapidity regions at a center-of-mass energy per nucleon pair of sqrt[s_{NN}]=8.16 TeV is measured by the LHCb experiment. The nuclear modification factor of prompt D^{0} mesons is determined as a function of the transverse momentum p_{T}, and the rapidity in the nucleon-nucleon center-of-mass frame y^{*}. In the forward rapidity region, significantly suppressed production with respect to pp collisions is measured, which provides significant constraints on models of nuclear parton distributions and hadron production down to the very low Bjorken-x region of ∼10^{-5}. In the backward rapidity region, a suppression with a significance of 2.0-3.8 standard deviations compared to parton distribution functions in a nuclear environment expectations is found in the kinematic region of p_{T}>6 GeV/c and -3.25
Collapse
|
75
|
Aaij R, Abdelmotteleb ASW, Abellan Beteta C, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Adlarson P, Afsharnia H, Agapopoulou C, Aidala CA, Aiola S, Ajaltouni Z, Akar S, Akiba K, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alvarez Cartelle P, Amalric R, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson M, Andreianov A, Andreotti M, Andreou D, Ao D, Archilli F, Artamonov A, Artuso M, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back JJ, Bailly-Reyre A, Baladron Rodriguez P, Balagura V, Baldini W, Baptista de Souza Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga IB, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Benane G, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Bernet Andres S, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Biesuz NV, Bifani S, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Blago MP, Blake T, Blanc F, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bolognani CS, Bolzonella R, Bondar N, Borgato F, Borghi S, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodzicka J, Brossa Gonzalo A, Brown J, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Cali S, Calladine R, Calvi M, Calvo Gomez M, Campana P, Campora Perez DH, Campoverde Quezada AF, Capelli S, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carli I, Carniti P, Carus L, Casais Vidal A, Caspary R, Casse G, Cattaneo M, Cavallero G, Cavallini V, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chapman MG, Charles M, Charpentier P, Chavez Barajas CA, Chefdeville M, Chen C, Chen S, Chernov A, Chernyshenko S, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Cid Vidal X, Ciezarek G, Ciullo G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Corredoira I, Corti G, Couturier B, Craik DC, Crkovská J, Cruz Torres M, Currie R, Da Silva CL, Dadabaev S, Dai L, Dai X, Dall'Occo E, Dalseno J, D'Ambrosio C, Daniel J, Danilina A, d'Argent P, Davies JE, Davis A, De Aguiar Francisco O, de Boer J, De Bruyn K, De Capua S, De Cian M, De Freitas Carneiro Da Graca U, De Lucia E, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Del Buono L, Delaney B, Dembinski HP, Denysenko V, Deschamps O, Dettori F, Dey B, Di Cicco A, Di Nezza P, Diachkov I, Didenko S, Dieste Maronas L, Ding S, Dobishuk V, Dolmatov A, Dong C, Donohoe AM, Dordei F, Dos Reis AC, Douglas L, Downes AG, Duda P, Dudek MW, Dufour L, Duk V, Durante P, Duras MM, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eirea Orro C, Eisenhardt S, Ejopu E, Ek-In S, Eklund L, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Fabiano F, Falcao LN, Fan Y, Fang B, Fantini L, Faria M, Farry S, Fazzini D, Felkowski LF, Feo M, Fernandez Gomez M, Fernez AD, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Fu J, Fuehring Q, Fulghesu T, Gabriel E, Galati G, Galati MD, Gallas Torreira A, Galli D, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Garau M, Garcia Martin LM, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales FA, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironella Gironell P, Giugliano C, Giza MA, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorelov IV, Gotti C, Grabowski JP, Grammatico T, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu AT, Greeven LM, Grieser NA, Grillo L, Gromov S, Gruberg Cazon BR, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Haefeli G, Haen C, Haimberger J, Haines SC, Halewood-Leagas T, Halvorsen MM, Hamilton PM, Hammerich J, Han Q, Han X, Hansen EB, Hansmann-Menzemer S, Hao L, Harnew N, Harrison T, Hasse C, Hatch M, He J, Heijhoff K, Heinicke K, Henderson C, Henderson RDL, Hennequin AM, Hennessy K, Henry L, Herd J, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Horswill J, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Iniukhin A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jaimes Elles SJ, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang E, Jiang X, Jiang Y, John M, Johnson D, Jones CR, Jones TP, Jost B, Jurik N, Juszczak I, Kandybei S, Kang Y, Karacson M, Karpenkov D, Karpov M, Kautz JW, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Khreich G, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kozachuk A, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kubat J, Kubis S, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kunde GJ, Kupsc A, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Landesa Gomez C, Lane JJ, Lane R, Lanfranchi G, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Lazzaroni M, Le Gac R, Lee SH, Lefèvre R, Leflat A, Legotin S, Lenisa P, Leroy O, Lesiak T, Leverington B, Li A, Li H, Li K, Li P, Li PR, Li S, Li T, Li Y, Li Z, Liang X, Lin C, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu Q, Liu S, Lobo Salvia A, Loi A, Lollini R, Lomba Castro J, Longstaff I, Lopes JH, Lopez Huertas A, López Soliño S, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lusiani A, Lynch K, Lyu XR, Ma L, Ma R, Maccolini S, Machefert F, Maciuc F, Mackay I, Macko V, Mackowiak P, Madhan Mohan LR, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Manca G, Mancinelli G, Mancuso C, Manuzzi D, Manzari CA, Marangotto D, Marchand JF, Marconi U, Mariani S, Marin Benito C, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, McGrath TH, McHugh NT, McNab A, McNulty R, Mead JV, Meadows B, Meier G, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Miao D, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Miralles T, Mitchell SE, Mitreska B, Mitzel DS, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monk M, Monroy IA, Monteil S, Morandin M, Morello G, Morello MJ, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muhammad E, Muheim F, Mulder M, Müller K, Murphy CH, Murray D, Murta R, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Neustroev P, Newcombe R, Nicolini J, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Novoa Fernandez J, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, O'Hanlon DP, Okamura S, Oldeman R, Oliva F, Onderwater CJG, O'Neil RH, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Ozcelik O, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Paolucci L, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pearce A, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Pereiro Castro A, Perret P, Petric M, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pham H, Philippov A, Piandani R, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pisani F, Pizzichemi M, Placinta V, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poliakova M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Popov S, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Punzi G, Qi HR, Qian W, Qin N, Qu S, Quagliani R, Raab NV, Rabadan Trejo RI, Rachwal B, Rademacker JH, Rajagopalan R, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Rebollo De Miguel M, Redi F, Reich J, Reiss F, Remon Alepuz C, Ren Z, Resmi PK, Ribatti R, Ricci AM, Ricciardi S, Richardson K, Richardson-Slipper M, Rinnert K, Robbe P, Robertson G, Rodrigues AB, Rodrigues E, Rodriguez Fernandez E, Rodriguez Lopez JA, Rodriguez Rodriguez E, Rolf DL, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Fernandez RA, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva JJ, Sagidova N, Sahoo N, Saitta B, Salomoni M, Sanchez Gras C, Sanderswood I, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead LG, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sciuccati A, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Sheng S, Shevchenko V, Shi B, Shields EB, Shimizu Y, Shmanin E, Shorkin R, Shupperd JD, Siddi BG, Silva Coutinho R, Simi G, Simone S, Singla M, Skidmore N, Skuza R, Skwarnicki T, Slater MW, Smallwood JC, Smeaton JG, Smith E, Smith K, Smith M, Snoch A, Soares Lavra L, Sokoloff MD, Soler FJP, Solomin A, Solovev A, Solovyev I, Song R, Souza De Almeida FL, Souza De Paula B, Spaan B, Spadaro Norella E, Spedicato E, Spiridenkov E, Spradlin P, Sriskaran V, Stagni F, Stahl M, Stahl S, Stanislaus S, Stein EN, Steinkamp O, Stenyakin O, Stevens H, Stone S, Strekalina D, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Tan Y, Taneja S, Tanner AR, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tilquin H, Tisserand V, T'Jampens S, Tobin M, Tomassetti L, Tonani G, Tong X, Torres Machado D, Tou DY, Trifonova E, Trilov SM, Trippl C, Tuci G, Tully A, Tuning N, Ukleja A, Unverzagt DJ, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, van Beuzekom M, Van Dijk M, Van Hecke H, van Herwijnen E, Van Hulse CB, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Vilasis-Cardona X, Vilella Figueras E, Villa A, Vincent P, Volle FC, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Vrahas C, Waldi R, Walsh J, Wan G, Wang C, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang X, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Websdale D, Wei Y, Weisser C, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson MK, Williams I, Williams M, Williams MRJ, Williams R, Wilson FF, Wislicki W, Witek M, Witola L, Wong CP, Wormser G, Wotton SA, Wu H, Wyllie K, Xiang Z, Xiao D, Xie Y, Xu A, Xu J, Xu L, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang X, Yang Y, Yang Z, Yang Z, Yeomans LE, Yeroshenko V, Yeung H, Yin H, Yu J, Yuan X, Zaffaroni E, Zavertyaev M, Zdybal M, Zenaiev O, Zeng M, Zhang C, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zou Q, Zucchelli S, Zuliani D, Zunica G. Measurement of the Time-Integrated CP Asymmetry in D^{0}→K^{-}K^{+} Decays. PHYSICAL REVIEW LETTERS 2023; 131:091802. [PMID: 37721849 DOI: 10.1103/physrevlett.131.091802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Accepted: 11/17/2022] [Indexed: 09/20/2023]
Abstract
The time-integrated CP asymmetry in the Cabibbo-suppressed decay D^{0}→K^{-}K^{+} is measured using proton-proton collision data, corresponding to an integrated luminosity of 5.7 fb^{-1} collected at a center-of-mass energy of 13 TeV with the LHCb detector. The D^{0} mesons are required to originate from promptly produced D^{*+}→D^{0}π^{+} decays, and the charge of the companion pion is used to determine the flavor of the charm meson at production. The time-integrated CP asymmetry is measured to be A_{CP}(K^{-}K^{+})=[6.8±5.4±1.6]×10^{-4} where the first uncertainty is statistical and the second systematic. The direct CP asymmetries in D^{0}→K^{-}K^{+} and D^{0}→π^{-}π^{+} decays, a_{K^{-}K^{+}}^{d} and a_{π^{-}π^{+}}^{d}, are derived by combining A_{CP}(K^{-}K^{+}) with the time-integrated CP asymmetry difference, ΔA_{CP}=A_{CP}(K^{-}K^{+})-A_{CP}(π^{-}π^{+}), and other inputs, giving a_{K^{-}K^{+}}^{d}=(7.7±5.7)×10^{-4},a_{π^{-}π^{+}}^{d}=(23.2±6.1)×10^{-4},with a correlation coefficient corresponding to ρ=0.88. The compatibility of these results with CP symmetry is 1.4 and 3.8 standard deviations for D^{0}→K^{-}K^{+} and D^{0}→π^{-}π^{+} decays, respectively. This is the first evidence for direct CP violation in a specific D^{0} decay.
Collapse
|